Hair loss (androgenetic): exosomes, PRP and what the registries show

The parting is widening, finasteride gives you pause, minoxidil is fine but underwhelming, and the clinic ads have moved on from transplants to vials: PRP, exosomes, “stem-cell serums”. Hair is where regenerative marketing runs hottest right now — and, unusually, where the trial registries show something worth knowing.

What the data says for this situation

Here is the useful anomaly in the working snapshot: for the site’s specific androgenetic alopecia query, registered exosome studies outnumber MSC studies. A broader all-alopecia query produces different totals, so the page deliberately shows the exact condition wording and retrieval date instead of presenting one universal count. Registry activity does not mean exosomes work; published human results remain small and short. PRP has a larger but preparation-dependent clinical literature, while established medical options still have the stronger outcome evidence.

Questions worth asking any provider

1. Against which baseline is success measured — photos, or counts per cm²?
2. How does this protocol compare with just optimising approved treatment first?
3. For exosome products: source cells, batch certification, and injectable status in this country?
4. Total cost across the full recommended course, not per session?

Red flags specific to this situation

• Density guarantees or “90% success” figures without published counts
• Session pricing that hides a 6–12 session course
• “Stem cell” branding on products containing conditioned media only

Cost context

PRP hair courses typically run €900–€2,500 per year in Europe; exosome protocols often more. Approved pharmacology costs a fraction of either — worth exhausting first.

FAQ

Do exosomes regrow hair?

Unproven. Registered studies exist, but the count changes with the alopecia subtype queried and published human results remain small pilots.

Is PRP for hair worth trying?

Trials show modest, variable benefit; it is the best-evidenced of the injectable options, well behind approved drugs.

→ Build questions for a specific provider · → Cost calculator

Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.